Overview

Our client, established in 2012, is a medical imaging software company that has developed a fully automated 3D visualization solution for quantitative Lung imaging diagnostics. Our client utilises Artificial Intelligence to turn standard greyscale medical imaging into rich visual maps of patient conditions with detailed quantitative reports that transform the way patients are discovered, diagnosed and treated. This technology has FDA, CE Mark and Health Canada certifications. The company has both strong management and a secure technology IP position.

For millions of patients every day, medical imaging is a vital part of their diagnosis and ongoing care decisions. This is a massive market with more than 1 Billion imaging studies (CT, MR, X-ray) requested in the U.S. and EU alone every year. Yet approximately 99% of all imaging diagnosis remains a purely manual reading process, one which is increasingly stressed by the demands of growing patient volumes and the need to lower healthcare costs. In India, China and other high growth healthcare markets, the use of imaging is rapidly outpacing the availability of qualified radiologists. Our client is closing this gap between the promise of imaging and the demands of modern healthcare using machine learning and AI to automate high-quality, personalised diagnosis of chronic lung conditions including COPD, Asthma, IPF & ILD’s, and Pulmonary Embolisms.

In China, Chronic Obstructive Pulmonary Disease (COPD) affects approx. 9% of the population, over 108 million patients and is the third leading cause of death, arising from exposure to smoke and air pollution. Interstitial Pulmonary Fibrosis (IPF) and other fibrotic lung diseases are also growing significantly due to general health and occupational conditions.

Our client’s commercially available Lung Density Analysis (LDA) and Lung Texture Analysis (LTA) are part of the company’s pulmonary portfolio supporting the diagnosis and care of COPD and IPF & ILD’s. LDA and LTA are proprietary analysis, backed by clinical publications and are fully automated requiring no physician intervention, but providing physicians with detailed imagery and quantitative staging of the patient’s lung condition to support diagnosis, treatment decisions and monitoring progression or treatment response.

Our client’s imaging diagnostics are fully automated and run on their Core Computing Platform (CCP). The CCP is a broad image processing platform which can be used for future growth and delivery of our client’s and a partner’s algorithms, if desired. The CCP can be run on premise or cloud based, and enables efficiency for individual physicians with scalability for large institutions and populations.

AI is transforming the diagnostic imaging industry. Our client offers world class technology with initial distribution agreements in the USA and Europe, and they have already established a strong joint venture with a leading interventional pulmonology Valve manufacturer to provide specific lung density analysis for emphysema patients in both the USA and Europe. Our client also provides imaging services to leading pharmaceutical companies for clinical trials and biomarker development efforts.

 Our client is seeking to raise funds for an equity position, and wishes to identify suitable domestic distribution partners to support their entry into the European and Indian markets, including a relationship to expand services for our client’s interventional pulmonary strategic entry into China. 

Exit Strategy - Our client would be looking for an IPO or trade sale within 4/5 years .